Vallon Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference

Rhea-AI Summary

Vallon Pharmaceuticals Inc. (NASDAQ: VLON) announced its participation in the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. David Baker, CEO, will present and engage in one-on-one meetings with registered investors. The presentation will be available for on-demand viewing starting March 9, 2021, at 7:00 AM ET and archived for 90 days. Vallon focuses on developing abuse-deterrent medications for CNS disorders, with its lead product candidate, ADAIR, aimed at treating ADHD and narcolepsy.

PHILADELPHIA, PA, March 03, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of CNS disorders, announced today that David Baker, President & Chief Executive Officer of Vallon will present at the virtual H.C. Wainwright Global Life Sciences Conference, which is taking place March 9 and 10, 2021.

In addition to the presentation, management will also be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.

The video webcast presentation will be available for viewing on-demand beginning Tuesday, March 9, 2021, at 7:00 AM ET for those registered for the event and will be accessible on the Events page of the Investors section of the Company's website (www.vallon-pharma.com) and will be archived for 90 days following the event. 

About Vallon Pharmaceuticals Inc.

Vallon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company, headquartered in Philadelphia, PA. The Company is focused on the development of new medications to help patients with central nervous system (CNS) disorders. The Company’s lead investigational product candidate, ADAIR, is a novel abuse deterrent formulation of amphetamine immediate release being developed for the treatment of ADHD and narcolepsy.

For more information about the company, please visit www.vallon-pharma.com.

Investor Contact:

JTC Team, LLC
Jenene Thomas
(833) 475-8247
vallon@jtcir.com

FAQ

When will Vallon Pharmaceuticals present at the H.C. Wainwright Global Life Sciences Conference?

Vallon Pharmaceuticals will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021.

What is ADAIR and how is it related to Vallon Pharmaceuticals?

ADAIR is Vallon Pharmaceuticals' lead investigational product candidate, designed as an abuse-deterrent formulation of amphetamine for treating ADHD and narcolepsy.

How can I watch Vallon's presentation at the conference?

Vallon's presentation will be available for on-demand viewing starting March 9, 2021, at 7:00 AM ET on their website.

How long will Vallon's conference presentation be available for viewing?

The presentation will be archived for 90 days following the event.

Who is the CEO of Vallon Pharmaceuticals?

David Baker is the President and Chief Executive Officer of Vallon Pharmaceuticals.